Lisata Therapeutics, Inc. filed Amendment No. 2 on Form 8-K/A on November 19, 2026, amending its September 17, 2026 current report to add unaudited pro forma combined statements of operations covering the nine months ended September 30, 2026 and the year ended December 31, 2025, in connection with the filing of a registration statement on Form S-3.

Key Highlights

  • Purpose of amendment: The filing adds unaudited pro forma combined statements of operations for the nine months ended September 30, 2026 and the year ended December 31, 2025, solely to support a registration statement on Form S-3.
  • Acquisition date: The original current report reported the completion of the acquisition of Marea Therapeutics, Inc., a Delaware corporation, on September 17, 2026.
  • Pro forma basis: The combined statement of operations treats the Marea acquisition as if it had occurred on January 1, 2025, according to the filing.
  • Marea financials audited by Ernst and Young LLP: Audited combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. for the years ended December 31, 2025 and 2024 were audited by Ernst and Young LLP.
  • New exhibit: Exhibit 99.6, the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2026 and the year ended December 31, 2025, is newly attached to this amendment.
  • Exchange listing: Lisata Therapeutics common stock, $0.001 par value per share, is listed on NASDAQ:LSTA under the Nasdaq Capital Market, as stated in the filing.

Lisata Therapeutics Supplements Marea Acquisition Disclosure With New Pro Forma Financials

According to the filing, this Amendment No. 2 on Form 8-K/A amends the current report originally filed on September 17, 2026, in which Lisata Therapeutics, Inc. reported the completion of its acquisition of Marea Therapeutics, Inc. The original report was previously amended by Amendment No. 1, filed on November 12, 2026, which included audited financial statements and earlier pro forma financial information required under Item 9.01(a) and Item 9.01(b) of Form 8-K.

The company disclosed that this second amendment is filed solely to add an unaudited pro forma condensed combined statement of operations for two periods: the nine months ended September 30, 2026, and the year ended December 31, 2025. The filing states that the nine-month pro forma combines the historical unaudited condensed statement of operations of Lisata Therapeutics for that period with the historical unaudited condensed statement of operations of Marea for the period January 1, 2026 through September 17, 2026. Both the nine-month and full-year pro forma statements are adjusted as if the acquisition had occurred on January 1, 2025. These are included as Exhibit 99.6.

The filing also incorporates by reference, from Amendment No. 1, the audited combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. for the years ended December 31, 2025 and 2024, audited by Ernst and Young LLP, as well as unaudited condensed combined interim financial statements as of June 30, 2026, and an earlier pro forma covering the six months ended June 30, 2026, and the year ended December 31, 2025. The company stated that except for the amendments to Item 9.01, all other disclosures in the original report remain unchanged. The filing was signed by David J. Mazzo, Ph.D., Chief Executive Officer, on November 19, 2026.

What Was Disclosed

Lisata Therapeutics filed Amendment No. 2 to its September 17, 2026 current report to attach unaudited pro forma combined statements of operations for the nine months ended September 30, 2026 and the year ended December 31, 2025, in connection with a Form S-3 registration statement filing.